Brief: Active Biotech gives update on laquinimod in Huntington's disease

Active Biotech AB publ

31/07/2018 08:22

July 31 (Reuters) - Active Biotech AB  ACTI.ST :
    * SAYS ACTIVE BIOTECH PROVIDES UPDATE ON LAQUINIMOD IN
HUNTINGTON'S DISEASE
    * SAYS PHASE 2 LEGATO-HD TRIAL EVALUATING SAFETY AND
EFFICACY OF
LAQUINIMOD AS A TREATMENT IN HUNTINGTON'S DISEASE (HD) DID NOT
MEET ITS PRIMARY ENDPOINT OF CHANGE FROM BASELINE AFTER 12
MONTHS OF TREATMENT
    * SAYS STUDY'S SECONDARY ENDPOINT, REDUCTION OF BRAIN
ATROPHY
(MEASURED BY CAUDATE VOLUME) WAS MET

Source text for Eikon:  ID:nGNE8fpLBT 
Further company coverage:  ACTI.ST 

 (Reporting By Stockholm newsroom)
 ((Stockholm.newsroom@thomsonreuters.com;))